{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:11:31Z","timestamp":1767791491413,"version":"3.49.0"},"reference-count":36,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the long-term safety and efficacy of upadacitinib over 5 years in Japanese patients with moderate-to-severe active rheumatoid arthritis and an inadequate response to stable doses of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs-IR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Japanese patients received upadacitinib 7.5, 15 or 30\u2009mg once per day or placebo for 12 weeks in a double-blind, randomised manner. Patients who completed the placebo-controlled phase entered a long-term extension phase during which they continued the same upadacitinib dose or were switched from placebo to upadacitinib 7.5, 15 or 30\u2009mg once per day. Blinding was maintained until dose switching from upadacitinib 30 mg to 15\u2009mg, prior to the regulatory approval of 15\u2009mg; the earliest switch occurred at week 132. Safety and efficacy were evaluated through week 260.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 121\/187 (64.7%) patients who entered the long-term extension phase completed the study. The types and frequency of adverse events were comparable with those reported at week 84 and in other studies of upadacitinib. The incidences of any adverse events, serious adverse events, infection and serious infection were numerically higher on upadacitinib 15 and 30\u2009mg than on 7.5\u2009mg. Clinical outcomes were improved and maintained over 260 weeks; Clinical Disease Activity Index clinical remission rates after 5 years were 40.8%, 26.5% and 28.0% on upadacitinib 7.5, 15 and 30\u2009mg, respectively (non-responder imputation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upadacitinib showed sustained efficacy with no new safety signals identified through 5 years of treatment and is a long-term treatment option for Japanese patients with rheumatoid arthritis and csDMARDs-IR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006213","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:05:12Z","timestamp":1762326312000},"page":"e006213","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02720523","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"},{"name":"Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Oribe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Oribe Clinic of Rheumatism and Medicine, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Konishi","sequence":"additional","affiliation":[{"name":"AbbVie GK, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumi","family":"Chonan","sequence":"additional","affiliation":[{"name":"AbbVie GK, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"AbbVie GK, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi S","family":"Camp","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026010700551692000_11.4.e006213.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"2026010700551692000_11.4.e006213.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026010700551692000_11.4.e006213.3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010700551692000_11.4.e006213.4","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac017"},{"key":"2026010700551692000_11.4.e006213.5","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1660028"},{"key":"2026010700551692000_11.4.e006213.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae544"},{"key":"2026010700551692000_11.4.e006213.7","first-page":"84","article-title":"Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis","volume":"9","author":"Louder","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2026010700551692000_11.4.e006213.8","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","article-title":"Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach","volume":"10","author":"Alten","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2026010700551692000_11.4.e006213.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2026010700551692000_11.4.e006213.10","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2026010700551692000_11.4.e006213.11","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1782049"},{"key":"2026010700551692000_11.4.e006213.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2026010700551692000_11.4.e006213.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2026010700551692000_11.4.e006213.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2026010700551692000_11.4.e006213.15","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026010700551692000_11.4.e006213.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"2026010700551692000_11.4.e006213.17","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate\u2010Naive Patients With Moderately\u2010to\u2010Severely Active Rheumatoid Arthritis (SELECT\u2010EARLY): A Multicenter, Multi\u2010Country, Randomized, Double\u2010Blind, Active Comparator\u2013Controlled Trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"2026010700551692000_11.4.e006213.18","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026010700551692000_11.4.e006213.19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","article-title":"Efficacy and safety of upadacitinib over 84\u2009weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)","volume":"23","author":"Kameda","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026010700551692000_11.4.e006213.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2026010700551692000_11.4.e006213.21","unstructured":"National Cancer Center Japan . Cancer statistics in Japan\u20132023. 2023. Available: https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2023_fig_E.pdf"},{"key":"2026010700551692000_11.4.e006213.22","first-page":"1","article-title":"Statistical methods in cancer research. Volume II--The design and analysis of cohort studies","volume":"82","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"key":"2026010700551692000_11.4.e006213.23","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115507"},{"key":"2026010700551692000_11.4.e006213.24","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.154"},{"key":"2026010700551692000_11.4.e006213.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2026010700551692000_11.4.e006213.26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"2026010700551692000_11.4.e006213.27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","article-title":"The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan","volume":"44","author":"Yamaoka","year":"2021","journal-title":"Drug Saf"},{"key":"2026010700551692000_11.4.e006213.28","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"2026010700551692000_11.4.e006213.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"2026010700551692000_11.4.e006213.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"2026010700551692000_11.4.e006213.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab139"},{"key":"2026010700551692000_11.4.e006213.32","unstructured":"Japan College of Rheumatology . Guideline for appropriate use of upadacitinib for all-case post marketing surveillance (in Japanese). 2024. Available: https:\/\/www.ryumachi-jp.com\/pdf\/guide_upadacitinib_240710.pdf"},{"key":"2026010700551692000_11.4.e006213.33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/14397595.2020.1847776","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-na\u00efve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026010700551692000_11.4.e006213.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204920"},{"key":"2026010700551692000_11.4.e006213.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063834"},{"key":"2026010700551692000_11.4.e006213.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054205"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:55:32Z","timestamp":1767776132000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-006213"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006213","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}